Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsSTU:6IB -6.27%80 Days Inventory is 239.87 as of Dec. 2025, which is 51% below its 10-year median of 490.54. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.19 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Innovent Biologics ranks worse than 58.31% on this metric.
The historical rank and industry rank for Innovent Biologics's Days Inventory or its related term are showing as below:
STU:6IB'
s Days Inventory Range Over the Past 10 Years
Min: 217.87 Med: 490.54 Max: 733.27
Current: 223.7
During the past 10 years, Innovent Biologics's highest Days Inventory was 733.27. The lowest was 217.87. And the median was 490.54.
STU:6IB's Days Inventory is ranked worse than 58.31% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs STU:6IB: 223.70
Innovent Biologics's Days Inventory
increased
from Dec. 2024 (163.97) to Dec. 2025 (239.87).
It might indicate that Innovent Biologics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Innovent Biologics's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.76.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Innovent Biologics's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.17.
Innovent Biologics (STU:6IB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Innovent Biologics's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Innovent Biologics's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Innovent Biologics Days Inventory Related Terms
Innovent Biologics Days Inventory Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6IB vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Innovent Biologics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (STU:6IB) has a Days Inventory of 239.87 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Innovent Biologics and its competitors. This is 51% below median its historical median of 490.54. Over the past decade, Innovent Biologics' Days Inventory has ranged from 217.87 to 733.27. According to the industry distribution chart, Innovent Biologics ranks #372 out of 638 companies in the Biotechnology industry, placing it in the top 58.3%.
Is Innovent Biologics' Days Inventory too high?
Innovent Biologics' current Days Inventory of 239.87 is 51% below median its 10-year median of 490.54. Over the past 10 years, this metric has ranged from a low of 217.87 to a high of 733.27. The Biotechnology industry median Days Inventory is 183.20. Innovent Biologics' value of 239.87 is 30.9% above this industry median. Based on the distribution chart, Innovent Biologics ranks #372 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #372 out of 638 companies for Days Inventory. This places Innovent Biologics in the lower half of its industry. The industry median Days Inventory is 183.20. Innovent Biologics' value of 239.87 is 30.9% above this benchmark. Historically, Innovent Biologics' own Days Inventory has ranged from 217.87 to 733.27 over the past decade. While the company's 10-year median is 490.54 vs. the industry median of 183.20, Innovent Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Days Inventory of 239.87 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Days Inventory is 239.87, which is 51% below median its own 10-year median of 490.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €9.69 — trading 13.4% below its estimated fair value. The current Days Inventory is 239.87, which is 51% below median its 10-year median of 490.54 and 30.9% above the Biotechnology industry median of 183.20. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current Days Inventory is 239.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €9.69 is trading 13.4% below its estimated GF Value™ of €11.19.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
Days Inventory: 239.87 (51% below median its 10-year median of 490.54)
GF Value™: €11.19 vs. price of €9.69 (13.4% below fair value)
Industry Position: 30.9% above the Biotechnology median (#372 of 638)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
